Abstract:FKBP51 is well-known as a cochaperone of Hsp90 machinery and implicated in many human diseases including stress-related diseases, tau-mediated neurodegeneration and cancers, which makes FKBP51 an attractive drug target for the therapy of FKBP51-associated diseases. However, it has been reported that only nature product rapamycin, cyclosporine A, FK506 and its derivatives exhibit good binding affinities when bound to FKBP51 by now. Given the advantages of peptide-inhibitors, we designed and obtained 20 peptide-inhibitor hits through structure-based drug design. We further characterized the interaction modes of the peptide-inhibitor hits on the FK1 domain of FKBP51 by biochemical and structural biology methods. Structural analysis revealed that peptide-inhibitor hits form U-shaped conformations and occupy the FK506 binding pocket and share similar interaction modes with FK506. Using molecular dynamics simulations, we delved into the interaction dynamics and found that hits are anchored to the FK506 binding pocket in a quite stable conformation. Meanwhile, it was shown that interactions between FK1 and peptide-inhibitor hits are mainly attributed to the hydrogen bond networks comprising I87 and Y113 and FPF cores of peptide-inhibitors involved extensive hydrophobic interactions. We presumed that the peptide design strategy based on the small molecule structure probably shed new lights on the peptide-inhibitor discovery of other targets. The findings presented here could also serve as a structural basis and starting point facilitating the optimization and generation of FKBP51 peptide-inhibitors with better bio-activities.Peptide-inhibitor hits were designed with small molecules published before used as the starting point through structure-based drug design and biochemically andstructurally characterized the interaction modes between the FK1 domain of FKBP51 and hitsDownload : Download high-res image (86KB)Download : Download full-size image

Discovery of a Potent Peptidic Cyclophilin A Inhibitor Trp-Gly-Pro

Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity.

Discovering Potent Small Molecule Inhibitors of Cyclophilin A Using De Novo Drug Design Approach

Short Cyclic Peptides Derived from the C-terminal Sequence of Α1-Antitrypsin Exhibit Significant Anti-Hiv-1 Activity

One Novel Quinoxaline Derivative As a Potent Human Cyclophilin A Inhibitor Shows Highly Inhibitory Activity Against Mouse Spleen Cell Proliferation

Identification of potent CypD inhibitors via pharmacophore based virtual screening, docking and molecular dynamics simulation

Cyclic Peptide Inhibitors of HIV-1 Capsid-Human Lysyl-Trna Synthetase Interaction.

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Inhibitors of Cyclophilin A: Current and Anticipated Pharmaceutical Agents for Inflammatory Diseases and Cancers

Computational design of cyclic peptides to inhibit protein-peptide interactions

Cyclophilin J PPIase Inhibitors Derived from 2,3-Quinoxaline-6 Amine Exhibit Antitumor Activity

Cyclosporin A-Based PROTACs Can Deplete Abundant Cellular Cyclophilin A without Suppressing T Cell Activation

Discovery of non-peptidic small molecule inhibitors of cyclophilin D as neuroprotective agents in Aβ-induced mitochondrial dysfunction

Discovery of pentapeptide-inhibitor hits targeting FKBP51 by combining computational modeling and X-ray crystallography

Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy

Multitargeted Drug Design Strategy for Discovery of Short-Peptide-based HIV-1 Entry Inhibitors with High Potency

Structure-Based Optimization of a Peptidyl Inhibitor Against Calcineurin-Nuclear Factor of Activated T Cell (NFAT) Interaction

Rational design of peptide inhibitors targeting HSP90–CDC37 protein–protein interaction

Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction

1.88 Å crystal structure of the C domain of hCyP33: A novel domain of peptidyl-prolyl cis–trans isomerase

Rapid in silico Design of Potential Cyclic Peptide Binders Targeting Protein-Protein Interfaces